



NDA 022399/S-005

**SUPPLEMENT APPROVAL**

**FULFILLMENT OF POSTMARKETING  
REQUIREMENTS**

Glaxo Group Limited  
d/b/a GlaxoSmithKline  
Attention: Debra H. Lake, M.S.  
Director, Regulatory Affairs  
PO Box 13398, Five Moore Drive  
Research Triangle Park, NC 27709

Dear Ms. Lake:

Please refer to your Supplemental New Drug Application (sNDA) received February 29, 2012, submitted pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Horizant (gabapentin enacarbil) Extended-Release Tablets.

We acknowledge receipt of your amendments dated April 23, 2012, June 22, 2012, July 6, 2012, November 9, 2012, January 4, 2013, January 9, 2013, February 5, 2013, and February 15, 2013.

This "Prior Approval" supplement provides for:

- Final study reports for Study RXP114111 (PMR 1588-7) and Study RXP115720 (PMR 1588-10).
- Revisions to the package insert based on the results of the studies referenced above.

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

**CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the package insert and Medication

Guide), with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eLIST may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

### **FULFILLMENT OF POSTMARKETING REQUIREMENTS**

We have received your submission dated February 29, 2012, containing the final reports for the following postmarketing requirements listed in the April 6, 2011 approval letter.

- 1588-7** A simulated driving trial in healthy adult subjects treated with 600 mg gabapentin enacarbil that includes active comparator and placebo arms.
- 1588-10** A clinical drug-drug interaction trial to evaluate the pharmacokinetic and the pharmacodynamic interaction between gabapentin enacarbil and morphine.

We have reviewed your submission and conclude that the above requirements were fulfilled.

### **PROMOTIONAL MATERIALS**

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit the following, in triplicate, (1) a cover letter requesting advisory comments, (2) the proposed materials in draft or mock-up form with annotated references, and (3) the package insert(s) to:

Food and Drug Administration  
Center for Drug Evaluation and Research  
Office of Prescription Drug Promotion (OPDP)  
5901-B Ammendale Road  
Beltsville, MD 20705-1266

You must submit final promotional materials and package insert(s), accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at <http://www.fda.gov/opacom/morechoices/fdaforms/cder.html>; instructions are provided on page 2 of the form. For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see <http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm>.

All promotional materials that include representations about your drug product must be promptly revised to be consistent with the labeling changes approved in this supplement, including any new safety information [21 CFR 314.70(a)(4)]. The revisions in your promotional materials should include prominent disclosure of the important new safety information that appears in the revised package labeling. Within 7 days of receipt of this letter, submit your statement of intent to comply with 21 CFR 314.70(a)(4) to the address above or by fax to 301-847-8444.

### **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Nicole L. Bradley, PharmD, Regulatory Project Manager, at (301) 796-1930.

Sincerely,

*{See appended electronic signature page}*

Russell G. Katz, MD  
Director  
Division of Neurology Products  
Office of Drug Evaluation I  
Center for Drug Evaluation and Research

ENCLOSURE:  
Content of Labeling

-----  
**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**  
-----

/s/  
-----

RUSSELL G KATZ  
03/27/2013